SIETES :: 91906 citas

Resultados de la búsqueda por BZDZ REFINAR BÚSQUEDA

1.

Née M, Avalos M, Luxcey A, Contrand B, Salmi L-R, Fourrier-Réglat A, Gadegbeku B, Lagarde E, Orriols L. Prescription medicine use by pedestrians and the risk of injurious road traffic crashes: A case-crossover study. PLOS Medicine 2017;14:18 de julio. [Ref.ID 101913]

2.

Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ 2017;358:j2941. [Ref.ID 101907]

3.

Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]

4.

Poudel DR, Acharya P, Ghimire S, Dhital R, Bharati R. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiol Drug Saf 2017;26:635-41. [Ref.ID 101626]

5.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

6.

Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia . Can Med Assoc J 2017;189:E517-518. [Ref.ID 101525]

7.

Taipale H, Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S. Risk of pneumonia associated with incident benzodiazepine use among community- dwelling adults with Alzheimer disease. Can Med Assoc J 2017;189:E519-529. [Ref.ID 101524]

8.

Soyka M. Treatment of benzodiazepine dependence. N Engl J Med 2017;376:1147-57. [Ref.ID 101503]

9.

Karaca-Mandic P, Meara E, Morden NE. The growing problem of co-treatment with opioids and benzodiazepines. BMJ 2017;356:j1224. [Ref.ID 101495]

10.

Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017;356:j760. [Ref.ID 101494]

11.

Maust DT, Gerlach LB, Gibson A, Kales HC, Blow FC, Olfson M. Trends in central nervous system–active polypharmacy among older adults seen in outpatient care in the United States. JAMA Intern Med 2017:13 de febrero. [Ref.ID 101408]

12.

Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016;111:1160-74. [Ref.ID 100800]

13.

Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016:22 de agosto. [Ref.ID 100584]

14.

Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010. Pharmacoepidemiol Drug Saf 2016;25:637-45. [Ref.ID 100393]

15.

de Souto Barredo P, Lapeyre-Mestre M, Cefac P, Vellas B, Rolland Y. Effects of a geriatic intervention aiming to improve quality care in nursing home on benzodiazepine use and discontinuation. Br J Clin Pharmacol 2016;81:759-67. [Ref.ID 100180]

16.

Anónimo. Cómo vender medicamentos peligrosos: el caso del Trankimazin. NoGracias 2015:27 de agosto. [Ref.ID 99809]

17.

Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am J Public Health 2015:17 de diciembre. [Ref.ID 99806]

18.

Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]

19.

Imfeld P, Bodmer M, Jick SS, Meier CR. Benzodiazepine use and risk of developing Alzheimer's disease or vascular dementia: a case-control analysis. Drug Saf 2015;38:909-19. [Ref.ID 99616]

20.

Anónimo. Drugs for insomnia. Med Lett Drugs Ther 2015;57:95-8. [Ref.ID 99452]